Segment Information (Tables)

9 Months Ended

Jul. 31, 2011

Segment Information [Abstract]

Segment profitability and segment assets

The profitability of each of the segments is measured after excluding restructuring and asset impairment charges, investment gains and losses, interest income, interest expense, acquisition and integration costs, non-cash amortization and other items as noted in the reconciliations below.

	Life Sciences			Chemical Analysis			Electronic Measurement		Total
	(in millions)
Three months ended July 31, 2011:
Total segment revenue	$	453		$	383		$	856	$	1,692
Varian acquisition deferred revenue fair value adjustment	$	-		$	(1	)	$	-	$	(1	)
Total net revenue	$	453		$	382		$	856	$	1,691
Segment income from operations	$	60		$	79		$	204	$	343
Three months ended July 31, 2010:
Total segment revenue	$	374		$	329		$	692	$	1,395
Varian acquisition deferred revenue fair value adjustment	$	(10	)	$	(1	)	$	-	$	(11	)
Total net revenue	$	364		$	328		$	692	$	1,384
Segment income from operations	$	56		$	69		$	127	$	252

	Life Sciences			Chemical Analysis			Electronic Measurement		Total
	(in millions)
Nine months ended July 31, 2011:
Total segment revenue	$	1,321		$	1,113		$	2,461	$	4,895
Varian acquisition deferred revenue fair value adjustment	$	(4	)	$	(4	)	$	-	$	(8	)
Total net revenue	$	1,317		$	1,109		$	2,461	$	4,887
Segment income from operations	$	169		$	216		$	551	$	936
Nine months ended July 31, 2010:
Total segment revenue	$	1,048		$	811		$	2,020	$	3,879
Varian acquisition deferred revenue fair value adjustment	$	(10	)	$	(1	)	$	-	$	(11	)
Total net revenue	$	1,038		$	810		$	2,020	$	3,868
Segment income from operations	$	159		$	193		$	285	$	637

The following table reflects segment assets under our management reporting system. Segment assets include allocations of corporate assets, including deferred tax assets, goodwill, other intangibles and other assets. Unallocated assets primarily consist of cash, cash equivalents, accumulated amortization of other intangibles and the valuation allowance relating to deferred tax assets.

	Life Sciences		Chemical Analysis		Electronic Measurement		Total
	(in millions)
Assets:
As of July 31, 2011	$	1,855	$	1,748	$	2,167	$	5,770
As of October 31, 2010	$	1,564	$	1,635	$	2,245	$	5,444

Reconciliation of reportable segment results to total enterprise from operations before taxes

The following table reconciles reportable segments' income from operations to Agilent's total enterprise income before taxes:

	Three Months Ended July 31,						Nine Months Ended July 31,
	2011			2010			2011			2010
	(in millions)
Total reportable segments' income from operations	$	343		$	252		$	936		$	637
Restructuring related costs		(2	)		(6	)		(2	)		(56	)
Transformational initiatives		(11	)		(14	)		(33	)		(29	)
Amortization of Intangibles		(29	)		(28	)		(85	)		(47	)
Acquisition and integration costs		(11	)		(50	)		(39	)		(77	)
Varian acquisition related fair value adjustments		(1	)		(33	)		(8	)		(33	)
Other		(8	)		(6	)		(11	)		(32	)
Interest income		3			3			10			9
Interest expense		(20	)		(24	)		(63	)		(69	)
Gain on sale of network solutions division, net		-			127			-			127
Other income (expense), net		17			6			34			19
Income before taxes, as reported	$	281		$	227		$	739		$	449